TRANSCRIPT FROM GOOGLE HANGOUT ON HIV PRE-EXPOSURE PROPHYLAXIS (PrEP) WITH DAMON JACOBS AND NELSON VERGEL Scott: Hello everybody. Scott Sillary here with Viral Marketing. I’m here with Nelson Vergel and Damon Jacobs. Welcome to the Power Hangout. It’s going to be fantastic. Nelson, tell us a little bit about what we’re going …
The HIV Prevention Pill: A Free Webcast on July 29, 6:30 PM (EDT) Activists and educators Damon Jacobs and Nelson Vergel will answer questions about the use of Truvada for HIV Pre-Exposure Prophylaxis (PrEP) covering research facts, misconceptions and access of this highly effective prevention tool. This webcast is of interest to the lay person …
The HIV Prevention Pill: A Free Webcast on July 29, 6:30 PM (EDT) Read More »
Impaired sperm motility in HIV-infected men: an unexpected adverse effect of efavirenz? Frapsauce C, et al. Hum Reprod. 2015. Authors Frapsauce C1, Grabar S2, Leruez-Ville M3, Launay O4, Sogni P5, Gayet V6, Viard JP7, De Almeida M8, Jouannet P8, Dulioust E1. Author information 1Laboratoire de Biologie de la Reproduction, Hôpital Broca-Cochin-Hôtel Dieu, Assistance Publique-Hôpitaux de …
Impaired sperm motility in HIV-infected men: an unexpected adverse effect of efavirenz? Read More »
Video: HIV Activist Raises Hope and Warnings in New Attachment Inhibitor Trial. Leading HIV activist Nelson Vergel raises hopes but also warns HIV salvage patients and their physicians about functional monotherapy risks in the Bristol-Meyers Squibb (BMS) new attachment inhibitor study (Fostemsavir, BMS-663068) currently enrolling (2015-2016). This innovative drug, along with Taimed’s ibalizumab, can be the …
HIV Activist Raises Hope and Warnings in New Attachment Inhibitor Trial. Read More »
Clin Infect Dis. (2015) doi: 10.1093/cid/civ171First published online: March 3, 2015 Impact of the Earliness of Antiretroviral Therapy Initiation During Primary HIV-1 Infection on the Decay of Cell-Associated HIV-DNA Moussa Laanani1,2, 1Inserm, CESP Centre for Research in Epidemiology and Population Health, U1018, Paris-Sud University, Le Kremlin-Bicêtre, France 2APHP, Department of Epidemiology and Public Health, Bicêtre Hospital, Le Kremlin-Bicêtre, France …
Starting HIV Medications Within First Weeks of Infection Decreases Hidden Virus Read More »
From Jules Levin: perhaps the biggest stories out of CROI from my perspective are the development of 2 new HIV therapies – the new attachment inhibitor & the new maturation inhibitors, as well as the safety & efficacy of TAF, and an important message out of CROI is that TAF can also be used in HCV coinfected patients as a replacement …
Most Important HIV Research Reports from CROI 2015 Read More »
January 29, 2015 Janssen Therapeutics, Division of Janssen Products, LP (Janssen), today announced the U.S. Food and Drug Administration (FDA) has approved PREZCOBIX™ (darunavir 800 mg/cobicistat 150 mg) tablets, an HIV-1 protease inhibitor combined with a CYP3A4 inhibitor, for the treatment of human immunodeficiency virus (HIV-1) in combination with other antiretroviral agents for treatment-naive and …
Prezcobix and Evotaz: Two New HIV Fixed Dose Combinations Approved this Week Read More »
Welcome to WordPress. This is your first post. Edit or delete it, then start blogging!
Published: November 14, 2014 DOI: 10.1371/journal.pone.0113031 Abstract Background We examined efficacy, toxicity, relapse, cost, and quality-of-life thresholds of hypothetical HIV cure interventions that would make them cost-effective compared to life-long antiretroviral therapy (ART). Methods We used a computer simulation model to assess three HIV cure strategies: Gene Therapy, Chemotherapy, and Stem Cell Transplantation (SCT), each …
Cost Effectiveness of Current HIV Cure Approaches Read More »
Findings from further studies using a reformulation of the only HIV vaccine that has ever worked in a large efficacy trial were presented at the recent HIV Research for Prevention conference (HIVR4P). They showed evidence of stronger antibody responses, and in-depth analysis of these responses shows that by further developing a similar vaccine it may be …
Groundbreaking HIV vaccine’s effects were real – and could be made to work better Read More »
Prevalence and risk factors of sleep disturbances in a large HIV-infected adult population. Authors Allavena C1, Guimard T2, Billaud E3, de la Tullaye S4, Reliquet V1, Pineau S3, Hüe H3, Supiot C1,Chennebault JM5, Michau C6, Hitoto H7, Vatan R8, Raffi F1. Author information Journal J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19576. doi: 10.7448/IAS.17.4.19576. eCollection 2014. Affiliation Abstract INTRODUCTION: Sleep disturbances are frequently reported in HIV-infected …
Shares of TaiMed Biologics Inc, which manufactures drugs to treat AIDS, soared 12.93 percent yesterday after its new TMB-355 drug for intravenous injection was granted orphan drug status in the US. The company’s shares closed at NT$151.2 yesterday, outperforming the over-the-counter benchmark index, which ended up 0.56 percent. The granting of orphan status could shorten …
Ibalizumab: First HIV Drug to Get Orphan Drug Status for Salvage Patients Read More »
